The FSHD jigsaw: are we placing the tiles in the right position?

• Published in: Current opinion in neurology Vol. 36; no. 5; p. 455
• Main Authors: Salsi, Valentina, Vattemi, Gaetano Nicola Alfio, Tupler, Rossella Ginevra
• Format: Journal Article
• Language: English
• Published: England 01.10.2023
• Subjects: Biomarkers; Drug Development; Homeodomain Proteins; Humans; Muscle, Skeletal - pathology; Muscular Dystrophy, Facioscapulohumeral - genetics
• ISSN: 1473-6551
• DOI: 10.1097/WCO.0000000000001176

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common myopathies, involving over 870,000 people worldwide and over 20 FSHD national registries. Our purpose was to summarize the main objectives of the scientific community on this topic and the moving trajectories of research from the past to the present. To date, research is mainly oriented toward deciphering the molecular and pathogenetic basis of the disease by investigating DUX4-mediated muscle alterations. Accordingly, FSHD drug development has been escalating in the last years in an attempt to silence DUX4 or to block its downstream effectors. Breakthroughs in the field include the awareness that new biomarkers and outcome measures are required for tracking disease progression and patient stratification. The need to develop personalized therapeutic strategies is also crucial according to the phenotypic variability observed in FSHD subjects. We analysed 121 literature reports published between 2021 and 2023 to assess the most recent advances in FSHD clinical and molecular research.